HLA class I and II genotype of the NCI-60 cell lines

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Adams, Sharon ^a   Robbins, Fu Meei ^a   Chen, Deborah ^a   Wagage, Devika ^a   Holbeck, Susan L ^b   Morse III, Herbert C ^c   Stroncek, David ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL CULTURE; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HLA TYPING; HUMAN; HUMAN CELL; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; STRAIN DIFFERENCE;

EID: 18144393498     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-11     Document Type: Article

References (46)

1. Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, McLemore TL, et al.: Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res 1988, 276:265-286.
2. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al.: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991, 83:757-766.
3. Grever MR, Schepartz SA, Chabner BA: The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992, 19:622-638.
4. Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, et al.: Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992, 12:1035-1053.
5. Monks A, Scudiero DA, Johnson GS, Paull KD, Sausville EA: The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 1997, 12:533-541.
6. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, Kohn KW, et al.: An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275: 343-349.
7. Gmeiner WH, Skradis A, Pon RT, Liu J: Cytotoxicity and in-vivo tolerance of FdUMP[10]: a novel pro-drug of the TS inhibitory nucleotide FdUMP. Nucleosides Nucleotides 1999, 18: 1729-1730.
8. Wells G, Seaton A, Stevens MF: Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents. J Med Chem 2000, 43:1550-1562.
9. Voeller DM, Grem JL, Pommier Y, Paull K, Allegra CJ: Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer Chemother Pharmacol 2000, 45:409-416.
10. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG: Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000, 70:113-122.
11. Salomon AR, Voehringer DW, Herzenberg LA, Khosla C: Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem Biol 2001, 8:71-80.
12. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al.: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001, 84:1424-1431.
13. Segraves NL, Robinson SJ, Garcia D, Said SA, Fu X, Schmitz FJ, et al.: Comparison of fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources. J Nat Prod 2004, 67:783-792.
14. Ross DD, Doyle LA: Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 2004, 6:105-107.
15. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al.: Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6:129-137.
16. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, et al.: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001, 98:10787-10792.
17. Weinstein JN: Pharmacogenomics. Teaching old drugs new tricks. N Engl J Med 2002, 343:1408-1409.
18. Weinstein JN: Searching for pharmacogenomics markers: the synergy between omic and hypothesis-driven research. Dis Markers 2002, 17:77-88.
19. Weinstein JN, Scherf U, Lee JK, Nishizuka S, Gwadry F, Bussey AK, et al.: The bioinformatics of microarray gene expression profiling. Cytometry 2002, 47:46-49.
20. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS: Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 2002, 18:405-412.
21. Blower PE, Yang C, Fligner MA, Verducci JS, Yu L, Richman S, et al.: Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J 2002, 2:259-271.
22. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, et al.: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003, 9:59-67.
23. Lee JK, Bussey KJ, Gwadry FG, Reinhold W, Riddick G, Pelletier SL, et al.: Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol 2003, 4:R82.
24. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, et al.: Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003, 63:8634-8647.
25. Weinstein JN, Pommier Y: Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol 2003, 326:909-920.
26. Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, et al.: Neural computing in cancer drug development: predicting mechanism of action. Science 1992, 258:447-451.
27. Bates SE, Fojo AT, Weinstein JN, Myers TG, Alvarez M, Pauli KD, et al.: Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol 1995, 121:495-500.
28. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al.: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997, 57:4285-4300.
29. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, et al.: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235.
30. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al.: A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000, 24:236-244.
31. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, et al.: Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003, 100:14229-14234.
32. Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001, 50:3-15.
33. Vinals C, Gaulis S, Coche T: Using in silico transcriptomics to search for tumor-associated antigens for immunotherapy. Vaccine 2001, 19:2607-2614.
34. Inozume T, Matsuzaki Y, Kurihara S, Fujita T, Yamamoto A, Aburatani H, et al.: Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients. Int J Cancer 2004.
35. Fang X, Shao L, Zhang H, Wang S: Web-based tools for mining the NCI databases for anticancer drug discovery. J Chem Inf Comput Sci 2004, 44:249-257.
36. Bettinotti M, Kim CJ, Lee K-H, Roden M, Cormier JN, Panelli MC, et al.: Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 1998, 161:877-889.
37. Kim CJ, Parkinson DR, Marincola FM: Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J Immunother 1998, 21:1-16.
38. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, et al.: Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994, 153:1225-1237.
39. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995, 16:487-494.
40. Garrido F, Cabrera T, Accola RS, Bensa JC, Bodmer WF, Dohr G, et al.: HLA and cancer: 12th International Histocompatibility Workshop study. In Genetic diversitity of HLA. Functional and medical implications Edited by: Charron D. Sevres, France: EDK; 1997:445-452.
41. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ: Multiple genetic alterations cause a frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000, 191:961-976.
42. Scudiero DA, Monks A, Sausville EA: Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 1998, 90:862.
43. Adams SD, Barracchini KC, Chen D, Robbins F, Wang L, Larsen P, et al.: Ambiguous allele combinations in HLA Class I and Class II sequence-based typing: when precise nucleotide sequencing leads to imprecise allele identification. J Transl Med 2004, 2: 30.
44. Ramon D, Braden M, Adams S, Marincola FM, Wang L: Pyrosequencing trade mark : A one-step method for high resolution HLA typing. J Transl Med 2003, 1:9.
45. Hicklin DJ, Marincola FM, Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999, 5:178-186.
46. Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S: Selective human leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 1999, 190:205-215.